Hope Rugo, MD

home / authors / hope-rugo-md

Articles

August 12th 2024

ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD

A panel of experts review ASCO 2024 and the need for future research in CDK4/6 inhibitors.

August 5th 2024

Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD

Dr. Dempsey discusses how CDK4/6 Inhibitors have impacted medication costs for breast cancer care, and the importance of implementing cost containment strategies to alleviate the situation.

August 5th 2024

Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD

Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.

July 29th 2024

How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD

Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.

July 29th 2024

Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD

A panel of experts discuss the variables of dosage and patient adherence in regards to managing toxicities from CDK4/6 inhibitors.

July 29th 2024

Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD

A medical expert navigates toxicity management in patients being treated with ribociclib.

July 29th 2024

Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD

Dr. Rugo details her management strategy in regards to GI toxicities.

July 10th 2024

Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD

Dr. Dempsey details how different types of endocrine therapies have impacted toxicities within her patients.

July 10th 2024

Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

Kirollos S. Hanna, PharmD, BCPS, BCOP Hope Rugo, MD Joyce O’Shaughnessy, MD Naomi Dempsey, MD

A panel of experts compare the toxicity profiles of abemaciclib and ribociclib.

Latest Updated Articles

Transgender | Image credit: Olga Tsikarishvili - stock.adobe.com

Published: August 18th 2025 | Updated: August 25th 2025

Conditional Economic Incentives Could Be Effective in Improving Adherence to Long-Acting PrEP in Transgender Adults

Semaglutide | Image credit: Peter Hansen - stock.adobe.com

Published: August 19th 2025 | Updated: August 22nd 2025

Semaglutide Not Associated With Increased Risk of Eye Disorders

On-body delivery system | Image credit: Enable Injections

Published: June 6th 2025 | Updated: August 18th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

drug shortages in the US | Image credit: OntheRun Photo - stock.adobe.com

Published: June 27th 2025 | Updated: July 1st 2025

Report Reveals Mounting Burdens of Drug Shortages on US Health System

Published: February 20th 2025 | Updated: February 21st 2025

Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP

Hands holding pack of cigarettes | Image credit: Nopphon – stock.adobe.com

Published: January 16th 2025 | Updated: January 29th 2025

FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

Do Not Sell My Information

Terms & Conditions